Company Overview and News

 
RIU GoodOilConference Perth to open with financing perspective from Westpac’s Mark Beeley

2018-09-12 proactiveinvestors.com.au
RIU GoodOilConference Perth will deliver more good oil for the industry during day two of the event, as Westpac Banking Corp’s (ASX:WBC) (NZE:WBC) (FRA:WBC) (NYSE:WBK) Westpac Institutional Bank energy and resources director Mark Beeley opens with a talk on Financing Considerations.
FAR TEG SXA SSLZY SGC MEL LCK BAS ICN ROG BRNGF MUR ICNOF COPJF AGYYF FARYF COE WBC CUEYF NWE STRXD STO WEBNF STRXF ELXPF WBK CUE CUEYY AJQ WBC OIEXF EXR KEY OEX BRU

 
RIU GoodOilConference Perth opens with financing perspective from Westpac’s Mark Beeley

2018-09-12 proactiveinvestors.com.au
RIU GoodOilConference Perth will deliver more good oil for the industry during day two of the event, as Westpac Banking Corp’s (ASX:WBC) (NZE:WBC) (FRA:WBC) (NYSE:WBK) Westpac Institutional Bank energy and resources director Mark Beeley opens with a talk on Financing Considerations.
FAR TEG SXA SSLZY SGC MEL LCK BAS ICN ROG BRNGF MUR ICNOF COPJF AGYYF FARYF COE WBC CUEYF NWE STRXD STO WEBNF STRXF ELXPF WBK CUE CUEYY AJQ WBC OIEXF EXR KEY OEX BRU

 
RIU GoodOilConference Perth and WA Petroleum Day to put oil and gas players centre stage

2018-09-07 proactiveinvestors.com.au
The RIU GoodOilConference in Perth next week will focus on the current state of the oil and gas industry, and the explorers and producers operating in Australia.
FAR TEG HZN SXA SGC SRNLY LIO TAOIF BAS ICN BEPTF MUR COMRF CPTLY COPJF AGYYF NWE STRXD STRXF CUE ADX CTP EXR HZR BRU PCL CVN TAO SUR MEL LCK HZNFF ROG LIOEF BRNGF ICNOF FARYF COE CUEYF COI ADXRF ELXPF BCHEY CVONF CUEYY BPT AJQ RLE OIEXF CVX KEY OEX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:OEX / OILEX LTD on message board site Silicon Investor.

Low Risk Low Stress Options Strategies Low Risk Low Stress Options Strategies Low Risk Low Stress Options Strategies oex oex oex
Yogiu0027s Signals Yogiu0027s Signals Yogiu0027s Signals NASDAQ SP DJ OEX INDICES TA ONLY! NASDAQ SP DJ OEX INDICES TA ONLY! NASDAQ SP DJ OEX INDICES TA ONLY!
BUY/SELL OEX, XAU BUY/SELL OEX, XAU BUY/SELL OEX, XAU BUY/SELL OEX, XAU BUY/SELL OEX, XAU BUY/SELL OEX, XAU
Daytrading OEX options with a method, not a trading system Daytrading OEX options with a method, not a trading system Daytrading OEX options with a method, not a trading system Help with OEX trading for Masteru0027s Thesis Help with OEX trading for Masteru0027s Thesis Help with OEX trading for Masteru0027s Thesis
DayTrading the OEX DayTrading the OEX DayTrading the OEX The OEX... gasp! The OEX... gasp! The OEX... gasp!